Novartis AG annual debt-to-ebitda ratio
2021
2022
2023
2024
2025
Novartis AG Debt-to-EBITDA Ratio Growth & History (NVS)
Novartis AG's debt-to-ebitda ratio was 1.65 for fiscal 2025.
View full Novartis AG company overviewNovartis AG annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.65 | −0.07 | −4.13% |
| 2024 | 2024-12-31 | 1.72 | 0.49 | +39.76% |
| 2023 | 2023-12-31 | 1.23 | −1.43 | −53.84% |
| 2022 | 2022-12-31 | 2.66 | 0.23 | +9.47% |
| 2021 | 2021-12-31 | 2.43 | — | — |
Novartis AG quarterly debt-to-ebitda ratio
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.18 | — | — |
| Q1 2026 | 2026-03-31 | 2.10 | — | — |
Novartis AG debt-to-ebitda ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, Novartis AG's debt-to-ebitda ratio decreased from 2.43 to 1.65, a change of −0.79. The latest reported quarter, Q2 2026, shows 2.18.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novartis AG source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...